---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Budget impact model"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Budget impact model. Covers Budget impact model discussion. 1 evidence topic quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics/budget-impact"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Budget impact model

<a id="heading-4.2"></a>

## 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

#### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

#### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

#### Summary

No budget impact model of AD109 was identified, and AD109 has no published price. The report holds evidence for these inputs of a future model:

- Eligible population: approximately 80 million U.S. people aged 30 to 69 years (prospectus) or 83.7 million U.S. adults aged 20 years and older with an AHI4 of 5 or more (Sönmez et al. 2025); approximately 23 million diagnosed patients active from 2019 to 2024, approximately 3 million new diagnoses per year, and approximately 10.5 million diagnosed but untreated (prospectus, from a National Sleep Foundation survey of 1,015 adults); and, for a PAP-intolerant or refusing population, the SynAIRgy intent-to-treat split of 411 (66.8%) with PAP intolerance and 205 (33.3%) with PAP refusal.
- Comparator and care costs: average costs of $2,105 per year for testing, appointments, treatment devices, and surgery if necessary (Frost & Sullivan 2016); payer costs per subject of $1,840 for a laboratory-based and $1,575 for a home-based diagnostic pathway (Kim et al. 2015); and an incremental lifetime cost of $42,953 for hypoglossal nerve stimulation (Pietzsch et al. 2015). The report quotes no acquisition price for tirzepatide.
- Discontinuation: across the two phase 3 trials combined, overall treatment discontinuation by Week 26 was 35.2% (227) with AD109 and 15.5% (100) with placebo, and treatment discontinuation due to treatment-emergent adverse events by Week 26 was 25.0% (163/653) and 6.7% (43/646); in the LunAIRo main cohort, overall discontinuation at month 12 was 46.5% with AD109 and 25.1% with placebo. For CPAP, termination (cessation of reimbursements) was 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years among 480,000 people (Pépin et al. 2021).

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/); [National Sleep Foundation (2025)](https://www.thensf.org/wp-content/uploads/2025/03/NSF-Inpsire-Report_2025-1.pdf); [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/); [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf); [Kim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4481018/); [Pietzsch et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4402668/); [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277); [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356); [Pépin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7957656/)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
